-
-
-
-
-
-
-
Lucid Diagnostics reports real-world data from 12,000 esophageal tests
-
-
-
-
-
-
-
Lucid Diagnostics (LUCD) Announces Proposed Public Offering of Common Stock
-
-
-
-
-
-
-
PAVmed (PAVM) and Subsidiary Veris Health Complete Private Placement Financing
-
-
-
-
-
-
-
Lucid Diagnostics (LUCD) Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
-
-
-
-
-
-
-
Lucid Diagnostics (LUCD) Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing in a Screening Popula
416,816 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

